

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 May 2006 (18.05.2006)

PCT

(10) International Publication Number
WO 2006/052722 A1

(51) International Patent Classification:

C07C 275/28 (2006.01) **C07D 213/82** (2006.01)
C07C 275/30 (2006.01) **C07D 333/38** (2006.01)
C07C 273/18 (2006.01) **A61K 31/17** (2006.01)
C07C 233/87 (2006.01) **A61P 3/10** (2006.01)
C07D 221/08 (2006.01)

(21) International Application Number:

PCT/US2005/039956

(22) International Filing Date:

4 November 2005 (04.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/626,389 9 November 2004 (09.11.2004) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia,
Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EVANS, Karen**
[US/US]; c/o GlaxoSmithKline, 1250 South Collegeville
Road, Po Box 5089, Collegeville, PA 19426 (US). **CI-
CHY-KNIGHT, Maria** [US/US]; c/o GlaxoSmithKline,
1250 South Collegeville Road, Po Box 5089, Collegeville,
PA 19426 (US). **COPPO, Frank, Teen** [US/US]; c/o Glaxo-
SmithKline, 1250 South Collegeville Road, Po Box 5089,
Collegeville, PA 19426 (US). **DWORNIK, Kate, Ann**
[GB/US]; c/o GlaxoSmithKline, Corporate Intellectual
Property Department, Five Moore Drive, Po Box 13398,
Research Triangle Park, NC 27709-3398 (US). **GALE,
Jennifer, Paul** [US/US]; c/o GlaxoSmithKline, 1250 South
Collegeville Road, Po Box 5089, Collegeville, PA 19426
(US). **GARRIDO, Dulce, Maria** [US/US]; c/o Glaxo-
SmithKline, Corporate Intellectual Property Department,
Five Moore Drive, Po Box 13398, Research Triangle Park,
NC 27709-3398 (US). **LI, Yue, Hu** [CN/US]; c/o Glaxo-
SmithKline, 1250 South Collegeville Road, Po Box 5089,
Collegeville, PA 19426 (US). **PATEL, Mehul, P.** [US/US];
c/o GlaxoSmithKline, 1250 South Collegeville Road, Po
Box 5089, Collegeville, PA 19426 (US). **TAVARES,
Francis X** [IN/US]; c/o GlaxoSmithKline, Corporate
Intellectual Property Department, Five Moore Drive, Po
Box 13398, Research Triangle Park, NC 27709-3398
(US). **THOMSON, Stephen, Andrew** [US/US]; c/o Glaxo-
SmithKline, Corporate Intellectual Property Department,
Five Moore Drive, Po Box 13398, Research Triangle Park,
NC 27709-3398 (US). **DICKERSON, Scott, Howard**
[US/US]; c/o GlaxoSmithKline, Corporate Intellectual

Property Department, Five Moore Drive, Po Box 13398,
Research Triangle Park, NC 27709-3398 (US). **PEAT,
Andrew, James** [US/US]; c/o GlaxoSmithKline, Corpo-
rate Intellectual Property Department, Five Moore Drive,
Po Box 13398, Research Triangle Park, NC 27709-3398
(US). **SPARKS, Steven, Meagher** [US/US]; c/o Glaxo-
SmithKline, Corporate Intellectual Property Department,
Five Moore Drive, Po Box 13398, Research Triangle Park,
NC 27709-3398 (US). **BANKER, Pierette** [US/US];
c/o GlaxoSmithKline, Corporate Intellectual Property
Department, Five Moore Drive, Po Box 13398, Research
Triangle Park, NC 27709-3398 (US). **COOPER, Joel,
P.** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual
Property Department, Five Moore Drive, Po Box 13398,
Research Triangle Park, NC 27709-3398 (US).

(74) Agents: **DADSWELL, Charles, E.** et al.; GlaxoSmithK-
line, Corporate Intellectual Property Department, Five
Moore Drive, Post Office Box 13398, Research Triangle
Park, North Carolina 27709 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

(57) Abstract: The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.

WO 2006/052722 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.